[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP23032164A - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Info

Publication number
ECSP23032164A
ECSP23032164A ECSENADI202332164A ECDI202332164A ECSP23032164A EC SP23032164 A ECSP23032164 A EC SP23032164A EC SENADI202332164 A ECSENADI202332164 A EC SENADI202332164A EC DI202332164 A ECDI202332164 A EC DI202332164A EC SP23032164 A ECSP23032164 A EC SP23032164A
Authority
EC
Ecuador
Prior art keywords
modulators
cystic fibrosis
conductance regulator
transmembrane conductance
pharmaceutical compositions
Prior art date
Application number
ECSENADI202332164A
Other languages
English (en)
Inventor
Thomas Cleveland
Jinglan Zhou
Haripada Khatuya
Mark Thomas Miller
Jason Mccartney
Sunny Abraham
Prasuna Paraselli
Ruah Sara Sabina Hadida
Anton V Gulevich
Alexander Russell Abela
Joe Tran
Yoshihiro Ishihara
Jeremy Clemens
Timothy A Dwight
Jaclyn Chau
Fabrice Pierre
Vito Melillo
Lev Tyler Dewey Fanning
Peter Grootenhuis (Fallecido)
Alina Silina
Corey Don Anderson
Vijayalaksmi Arumugam
Paul Krenitsky
Bryan A Frieman
Johnny Uy
Lino Valdez
Timothy Richard Coon
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP23032164A publication Critical patent/ECSP23032164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.
ECSENADI202332164A 2020-10-07 2023-05-02 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística ECSP23032164A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063088935P 2020-10-07 2020-10-07

Publications (1)

Publication Number Publication Date
ECSP23032164A true ECSP23032164A (es) 2023-06-30

Family

ID=78771139

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202332164A ECSP23032164A (es) 2020-10-07 2023-05-02 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Country Status (20)

Country Link
US (1) US20230382925A1 (es)
EP (1) EP4225764A1 (es)
JP (1) JP2023545081A (es)
KR (1) KR20230104618A (es)
CN (1) CN116783204A (es)
AR (1) AR123709A1 (es)
AU (1) AU2021358063A1 (es)
BR (1) BR112023006381A2 (es)
CA (1) CA3197857A1 (es)
CL (1) CL2023000984A1 (es)
CO (1) CO2023005734A2 (es)
CR (1) CR20230200A (es)
DO (1) DOP2023000066A (es)
EC (1) ECSP23032164A (es)
IL (1) IL301755A (es)
MX (1) MX2023004074A (es)
PE (1) PE20231185A1 (es)
TW (1) TW202233635A (es)
UY (1) UY39460A (es)
WO (1) WO2022076624A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
AU2023249173A1 (en) * 2022-04-06 2024-10-03 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056779A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
TW202421102A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PT2489659T (pt) 2004-06-24 2018-03-07 Vertex Pharma Moduladores de transportadores de cassete de ligação a atp
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
SI3219705T1 (sl) 2005-12-28 2020-08-31 Vertex Pharmaceuticals Incorporated Farmacevtski sestavki amorfne oblike N-(2,4-bis(1,1-dimetiletil)-5- hidroksifenil)-1,4-dihidro-4-oksokinolin-3-karboksamid
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
AU2007249269A1 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS60229B1 (sr) 2007-12-07 2020-06-30 Vertex Pharma Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzojeve kiseline
ES2625957T3 (es) 2007-12-07 2017-07-21 Vertex Pharmaceuticals Incorporated Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos
KR20110042356A (ko) 2008-08-13 2011-04-26 버텍스 파마슈티칼스 인코포레이티드 제약 조성물 및 그의 투여
US8716338B2 (en) 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2742821C (en) 2008-11-06 2018-10-23 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
SG193156A1 (en) 2009-03-20 2013-09-30 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP2563778B1 (en) 2010-03-25 2016-08-24 Vertex Pharmaceuticals Incorporated Crystalline form of (r)-1(2,2 -difluorobenzo[d][1,3]dioxol-5yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2yl)-1h-indol-5yl)cyclopropanecarboxamide
EP2556009B1 (en) 2010-04-09 2016-02-10 Ekso Bionics Exoskeleton load handling system and method of use
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
US20120064157A1 (en) 2010-08-27 2012-03-15 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2012158885A1 (en) 2011-05-18 2012-11-22 Concert Pharmaceuticals Inc. Deuterated derivatives of ivacaftor
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
TW201422253A (zh) 2012-11-02 2014-06-16 Vertex Pharma 治療ｃｆｔｒ介導疾病之醫藥組合物
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
PT3925607T (pt) 2014-04-15 2023-09-26 Vertex Pharma Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
BR112018005454A2 (pt) 2015-09-21 2018-10-09 Vertex Pharmaceuticals Europe Ltd administração de potencializadores de cftr deuterados
CA3041819A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
IL294042A (en) * 2018-02-15 2022-08-01 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
TWI848092B (zh) * 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
KR20220064366A (ko) * 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태

Also Published As

Publication number Publication date
US20230382925A1 (en) 2023-11-30
UY39460A (es) 2022-05-31
TW202233635A (zh) 2022-09-01
JP2023545081A (ja) 2023-10-26
PE20231185A1 (es) 2023-08-11
WO2022076624A1 (en) 2022-04-14
KR20230104618A (ko) 2023-07-10
IL301755A (en) 2023-05-01
AR123709A1 (es) 2023-01-04
CO2023005734A2 (es) 2023-07-21
AU2021358063A1 (en) 2023-05-18
DOP2023000066A (es) 2023-07-09
CR20230200A (es) 2023-07-13
CL2023000984A1 (es) 2023-11-24
BR112023006381A2 (pt) 2023-09-26
CA3197857A1 (en) 2022-04-14
CN116783204A (zh) 2023-09-19
EP4225764A1 (en) 2023-08-16
MX2023004074A (es) 2023-07-05

Similar Documents

Publication Publication Date Title
ECSP23032164A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2023005736A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2022002749A2 (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quística
CL2023000988A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39374A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39458A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39461A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39456A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39723A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
UY39455A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
BR112021019102A2 (pt) Composições e métodos para tratamento de fibrose cística
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
CL2021002078A1 (es) Composiciones y métodos para la administración de polipéptidos cftr.
CO2024013546A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
BR112016029926A2 (pt) administração nasal
CO2021000037A2 (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
AR129032A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39521A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39603A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso